<div><p><b>Background: </b>Retatrutide (RETA; LY3437943) is a novel triple agonist of the GIP, GLP-1 and glucagon receptors under investigation for obesity treatment. A 48-week phase 2 obesity study demonstrated weight loss of −22.8% and −24.2% with RETA 8 and 12 mg. We report effects of RETA on liver fat (LF) and correlations with metabolic measures in subjects with MASLD included in this trial.</p>

<div><p><b>Background: </b>Telemedicine removes geographic and temporal obstacles to healthcare access. Few randomized trials have evaluated telemedicine effectiveness for underserved populations. We compared sustained virological response (SVR12) rates for hepatitis C virus (HCV) infection among persons with opioid use disorder through facilitated telemedicine (FTM) versus offsite liver specialist referral (usual care or UC).</p>

<div><p><b>Background: </b>Initial recommendations from scientific societies cautioned against procurement of livers from COVID-19(+) donors. Growing evidence supports the short-term safety of liver transplantation from COVID-19(+) donors. We described usage of liver transplants from COVID-19(+) donors during the COVID-19 pandemic and characterized associated transplant outcomes using data from the United Network for Organ Sharing registry.</p>

<div><p><b>Background:</p> </b><p>To develop a non-invasive multivariate models based on Three-dimensional MR elastography (3D-MRE) to determine portal hypertension (PH), particularly to diagnose clinically significant portal hypertension (CSPH, HVPG&gt;10mmHg) and severe portal hypertension (SPH, HVPG&gt;12mmHg), using HVPG as the gold standard.</p>

<div><p><strong><b>Background:</strong> </b>Early recurrence of hepatocellular carcinoma (HCC) after surgical resection compromises patient survival. Timely detection of minimal residual tumor is helpful in recurrence monitoring and evaluating treatment strategies. This study examined the feasibility of virus-host chimera DNA (vh-DNA) generated from integration sites of hepatitis B virus (HBV) in the HCC chromosome as a personalized circulating biomarker for residual tumors after surgery.</p>

<div><p><b>Background:</p> </b><p>Biliary atresia (BA) is the principal indication for liver transplantation in children, yet there is little information regarding its underlying etiology. Recent data strongly places BA as a developmental cholangiopathy suggesting that there are gene variant contributions that can be discovered using modern gene sequencing and analytical technologies.

<div><p><strong><b>Background:</strong> </b>Liver fibrosis is the consequence of chronic liver diseases that can progress to cirrhosis and liver failure. However, the role and mechanism of gut leakiness in liver fibrosis are poorly understood, and there is no FDA-approved drug to treat liver fibrosis.

<div><p><b>Background: </b>The gut-liver interaction has emerged as a critical component in alcohol-associated liver disease (ALD) pathogenesis. The central mediators are the gut luminal antigens, especially endotoxins that translocate to the liver. This occurs because of (i) compromised gut barrier integrity due to epithelial tight junction (TJ) disruption; and (ii) qualitative/quantitative gut microbiota changes and increased production of pathogenic antigens.</p>

<div><p><strong><b>Background:</strong> </b>Albumin has been shown to modulate systemic inflammation in patients with decompensated liver cirrhosis receiving infusions of this protein as therapy. Although the anti-inflammatory effect of albumin has been described to be secondary to its internalization into mononuclear leukocytes, the cell type and the mechanism by which albumin is internalized by these immune cells are at present unknown.</p>

<div><p><b>Background: </b>PSC is an archetypical example of a disease with an impaired gut-liver axis and PSC patients with or without inflammatory bowel disease exhibit enteric microbial dysbiosis. Gut microbiota produce diverse metabolic products but how microbes influence PSC disease progression is unclear. By screening bacterial species (sp.) in a transwell gut-liver axis model, we identified novel <em>Leuconostoc sp</em>. (LB-P8) that may have anti-fibrotic properties via inhibition of TGF-β/SMAD signaling.